非agenarians经股动脉与经心尖TAVR结局分层分析
基于2011-2013年Medicare数据库接受TAVR的18283例患者,19.3%为90岁及以上。90岁及以上患者30天和1年死亡率略高于年轻患者(8.4% vs 5.9%;25.4% vs 21.5%),但75%存活至1年;在该人群中经心尖入路较经股动脉入路结局更差。
要点
- 90岁及以上患者TAVR后30天死亡率8.4%,1年死亡率25.4%,75%存活至1年。
- 经心尖TAVR是非agenarians 30天死亡(OR 1.94)和再入院(OR 1.46)的独立预测因素。
- 非agenarians经股动脉TAVR较经心尖入路30天和1年死亡率更低,出院回家比例更高。
核心结论
- 非agenarians TAVR后30天和1年死亡率略差于年轻患者,但75%存活至1年,长期生存仍令人鼓舞。
- 在非agenarians中,经心尖TAVR与更差结局相关。
研究设计与样本
- 回顾性队列研究,纳入2011年11月至2013年接受TAVR的65岁及以上患者,共18283例,其中19.3%为90岁及以上。
主要发现
- 90岁及以上患者30天死亡率为8.4%,低于90岁患者为5.9%(p=0.0001);1年死亡率分别为25.4%和21.5%(p=0.0001),OR 1.47(95%CI 1.28-1.70,p=0.0001)。
- 90岁及以上患者起搏器植入率更高(11.1% vs 8.3%,p=0.0001)。
- 在非agenarians中,经股动脉TAVR较经心尖入路30天死亡率更低(7.2% vs 13.6%,p=0.0001),1年死亡率更低(23.8% vs 31.6%,p=0.0001),出院回家比例更高(54.4% vs 34.1%,p=0.0001),30天再入院率更低(23.8% vs 31.8%,p=0.0001)。
- 校正患者特征后,经心尖TAVR是30天死亡率(OR 1.94,95%CI 1.48-2.56,p=0.0001)和再入院(OR 1.46,95%CI 1.19-1.80,p=0.0003)的独立预测因素。
临床怎么用
- 对非agenarians行TAVR时,优先考虑经股动脉入路以降低死亡和再入院风险。
- 非agenarians TAVR后需关注起搏器植入风险。
局限性
- 研究基于Medicare数据库,可能不涵盖所有TAVR患者。
- 回顾性设计,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival and other outcomes of nonagenarians undergoing transcatheter aortic valve replacement (TAVR) in the Medicare population are unclear. METHODS: Patients aged 65 years and older who underwent TAVR from November 2011 through 2013 were considered for inclusion. RESULTS: The study consisted of 18,283 patients and 19.3% were aged 90 years or older. Compared with patients younger than 90 years, patients 90 years or older were less likely to have a number of comorbidities, including previous myocardial infarction (17.5% versus 21.8%), previous coronary artery bypass grafting (20.0% versus 35.0%), and chronic obstructive pulmonary disease (25.4% versus 39.0%) among others. The 30-day and 1-year mortality rates were 8.4% versus 5.9% (p = 0.0001) and 25.4% versus 21.5% (p = 0.0001) in the older and younger groups, respectively (odds ratio [OR] 1.47, 95% confidence interval [CI]: 1.28 to 1.70, p = 0.0001). Patients 90 years and older were more likely to undergo pacemaker insertion (11.1% versus 8.3%, p = 0.0001). Among nonagenarians, compared with the transapical group, patients undergoing transfemoral TAVR had lower 30-day (7.2% versus 13.6%, p = 0.0001) and 1-year (23.8% versus 31.6%, p = 0.0001) mortality rates, were more likely to be discharged home (54.4% versus 34.1%, p = 0.0001), and had lower 30-day readmission rates (23.8% versus 31.8%, p = 0.0001). After adjustment for patient characteristics, transapical TAVR was an independent predictor of 30-day mortality rate (OR 1.94, 95% CI: 1.48 to 2.56, p = 0.0001) and readmission (OR 1.46, 95% CI: 1.19 to 1.80, p = 0.0003). CONCLUSIONS: In patients undergoing TAVR, although 30-day and 1-year mortality rates were slightly worse for nonagenarians than their younger counterparts, long-term survival was still encouraging, with 75% of nonagenarians living to 1 year. Transapical TAVR was associated with worse outcomes in nonagenarians.
引用
- McNeely C, Zajarias A, Robbs R, et al. Transcatheter Aortic Valve Replacement Outcomes in Nonagenarians Stratified by Transfemoral and Transapical Approach. Ann Thorac Surg. 2017. PMID: 28450135. doi:10.1016/j.athoracsur.2017.02.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。